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Zusammenfassung
Maligne Hirntumoren, insbesondere die malignen Glio-
me, haben trotz multimodaler Therapieansätze eine un-
verändert schlechte Prognose. Diese Aggressivität korre-
liert mit der Tatsache, daß maligne Gliome zu den gefäß-
reichsten Tumoren zählen, die wir kennen. Die Quantifi-
zierung der Gefäßdichte in diesen Tumoren erlaubte die
Korrelation zur Überlebenszeit der Patienten. Da das Tu-
morwachstum von einer begleitenden Neovaskularisie-
rung abhängt, wurden erste experimentelle Therapiean-
sätze durchgeführt, um das Tumorwachstum durch Inhi-
bierung der Neovaskularisierung zu verhindern. Inhibito-
ren der Angiogenese, z.B. TNP-470, Suramin und
Angiostatin hemmen die Proliferation von Endothelzel-
len und die Ausbildung eines funktionsfähigen Gefäßbet-
tes. Erste experimentelle Ansätze haben ihre tumorstati-
sche Wirksamkeit in vivo bewiesen. Zur klinischen Be-
handlung wären diese Substanzen in Verbindung mit be-
stehenden Therapien einsetzbar, insbesondere für die
Behandlung multipler Tumoren und zur postoperativen
Therapie. Diese Übersichtsarbeit beschreibt die neuesten
anti-angiogenen Therapiekonzepte besonders mit Hin-
blick auf Substanzen, die in ersten klinischen Studien
eingesetzt werden.
Key Words 
Angiogenesis · Brain tumor · Metastases · 
Clinical trial
Summary
Malignant brain tumors, especially malignant gliomas,
have a poor prognosis, a fact which has remained un-
changed over the last decades despite the employment
of multimodal therapeutic approaches. Malignant
gliomas are among the most vascularized tumors known
and the amount of vascularization has been correlated to
their prognosis. Since tumor growth is dependent on
concomitant vascularization, recent experimental studies
have focused on the use of anti-angiogenic molecules as
a novel strategy in brain tumor therapy. Angiogenesis in-
hibitors target at proliferating endothelial cells and sup-
press the formation of a sufficient vascular bed. In-
hibitors such as TNP-470, suramin and angiostatin have
shown their therapeutic potential in experimental stud-
ies. In a clinical setting, they could be applied for the
treatment of multiple tumors or postsurgically as an ad-
juvant therapy to prevent recurrence. This article dis-
cusses presently available anti-angiogenic agents, em-
phasizing on substances already in clinical trials. 
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Introduction
It is well recognized that angiogenesis is essential for tumor
growth and development of metastasis. With the exception of
avascular leptomeningeal tumor spread, tumors cannot grow
beyond a certain size without concurrent extension of their vas-
cular bed. Most current treatment concepts aim at the neoplas-
tic cell compartment and rely on cytoreductive measures. On
the contrary, anti-angiogenic treatment focuses on the endothe-
lial cell compartment. Endothelial cells are recruited by solid
tumors from the existing vasculature and from endothelial pre-
cursor cells. Tumor-associated endothelial cells are non-neo-
plastic cells although they exhibit some features of malignancy
such as proliferation and invasiveness. While heterogenous tu-
mors are prone to resistance through clonal selection, endothe-
lial cells represent a homogenous non-neoplastic cell compart-
ment that is less likely to be subject to resistance. Endothelial
cells line the inner part of blood vessels and are easily accessible
for circulating drugs, especially in comparison to tumor cells.
With special respect to brain tumors, endothelial cells can be
targeted independently of the blood-brain barrier. 
Solid tumors cannot grow beyond a size of 1–3 mm in diame-
ter without acquisition of new blood vessels, thus inhibition of
angiogenesis would be sufficient to keep a majority of intra-
cerebral solid tumors asymptomatic.
Brain tumors are among the most highly vascularized tumors
known [1]. Li et al. [2] in 1994 reported a correlation of mi-
crovessel grading with cerebrospinal fluid levels of basic
fibroblast growth factor (bFGF), and with the risk of recur-
rence of death in a variety of pediatric brain tumor types.
Leon et al. [3] in 1996 reported a negative correlation between
increasing microvessel counts and disease-free survival. They
demonstrated that vascularity represents an independent
prognostic indicator.
The forementioned data show that tumor-related vessel
growth represents an attractive new therapeutic target. A
number of anti-angiogenic treatment strategies have been de-
veloped and will be discussed. 
Positive Regulators of Angiogenesis
Angiogenesis is a complex multifaceted biological process
and, thus, offers potential therapeutic targets at multiple lev-
els. After neoplastic transformation of a normal cell has oc-
curred, proliferation ensues. As long as proliferation and cell
death remain balanced, the tumor does not expand nor does it
need in-growing vessels [4]. This dormant state is of variable
duration and ends as soon as angiogenic signals are released
and neovascularization ensues, this phenomenon is referred to
as the angiogenic switch. Angiogenic growth factors produced
by tumor cells induce endothelial cell proliferation. Along
with the properties of the surrounding matrix, growth factors
determine the success of tumor-related angiogenesis and en-
dothelial cell recruitment. A growing number of molecules
with angiogenic properties produced by tumor cells as well as
endothelium-specific angiogenic molecules have been identi-
fied. While a comprehensive list is given in table 1, this
overview focuses mainly on molecules that are already sub-
ject of clinical investigation. 
VEGF and VEGF Receptors
Vascular endothelial growth factor (VEGF) represents an im-
portant signal molecule during initiation and maintenance of
angiogenesis by hypoxia [5]. The VEGF receptors belong to a
family of endothelial receptor tyrosine kinases which are acti-
vated upon high-affinity binding of the growth factors to their
cognate receptors. VEGF and its receptors are expressed at
high levels in many types of human tumors, including gliomas
[6], where they exhibit a cell-type specificity [7]. Whereas
VEGF is secreted by tumor cells as well as by normal tissue in
response to hypoxia, the VEGF receptor KDR/flk-1 is ex-
pressed on the surface of activated endothelial cells, especially
at tumor sites [8]. Forced overexpression of VEGF by tumor
cells has been shown to enhance their tumorigenic potential
[5, 9]. The cellular effects of VEGF are mediated by at least
three different receptors VEGF-R-1, -2, and -3, also termed
flt-1, flk-1/KDR, and flt-4, respectively. In addition, VEGF ex-
pression has been shown to represent an independent prog-
nostic factor for the outcome of pancreatic, ovarian, and mam-
mary ductal carcinoma in situ, as well as of metastasizing tes-
ticular cancer and of brain tumors [10]. 
In brain tumors, VEGF was shown to be overexpressed in
gliomas compared to normal tissue [7, 10, 11]. Furthermore,
expression of VEGF has been reported to correlate with mi-
crovessel density in gliomas and meningiomas [10]. Consistent
with its regulatory role in vessel permeability, VEGF expres-
sion also correlates with tumorigenic edema in cerebral metas-
tases, meningiomas, and gliomas [12–15]. Based on immuno-
histochemical expression data on 162 astrocytic gliomas,
VEGF expression has been correlated with overall survival
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Vascular endothelial growth factor (VEGF)
Acidic and basic FGF (aFGF, bFGF) 
Transforming growth factor alpha and beta
(TGF-α and -β)
Angiogenin 
Epidermal growth factor (EGF) 
Scatter factor / HGF 
Placenta-derived growth factor (PlGF) 
Interleukin-8 (Il-8) 
Tumor necrosis factor (TNF) 
Insulin-like growth factor (IGF) 
Platelet derived growth factor (PDGF)
Prostaglandins E1 and E2
Androgen, estrogen 
Angiopoietin-1 (ANG-1) 
ANG-2 in the presence of VEGF
Table 1. Angiogenic
factors
but was not shown to be an independent prognostic factor in
gliomas [16]. In low-grade astrocytomas, however, VEGF ex-
pression correlates with the outcome [17]. 
Several lines of experimental evidence suggest that targeting
VEGF may lead to highly effective anti-angiogenic treatment.
Thus, antibodies against VEGF, VEGF-R, and VEGF-diph-
theria toxin conjugates exert an inhibitory effect on the
growth of tumor xenografts in mice [18–20]. The retroviral in-
troduction of VEGF antisense-RNA into glioma cells in a
mouse model resulted in the inhibition of tumor growth and
prolongation of survival time [21]. A 16 kDa prolactin frag-
ment has been demonstrated to interfere with VEGF-induced
signalling pathways by inhibiting phosphorylation of two mi-
togen-activated protein kinases (MAPK) by VEGF [22].
Whether this endogenously produced anti-angiogenic mole-
cule can be employed for therapeutic use remains to be inves-
tigated.
Antibodies against human VEGF and VEGF receptors are
currently being tested in phase II/III clinical trials (table 2).
While some of the recently reported VEGF-R antagonists
such as the porphyrin antagonist TMPP or short peptides
identified by phage display have not yet reached the clinical
arena, other low-molecular-weight inhibitors of VEGF-R ty-
rosine kinases such as SU5416, SU6668, PTK787, and ZD4190
are already under clinical investigation (table 2). 
Tie – Receptors and Angiopoietins
Tie-1 and Tie-2, tyrosine kinases with immunoglobulin and
epidermal growth factor homology domains, resemble the
VEGF receptors in that they constitute endothelial-cell-spe-
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Table 2. Angiogenesis inhibitors in clinical trials
Drug Trial Mechanism Company
Marimastat phase III synthetic inhibitor of MMPs British Biotech
AG-3340 phase II + III synthetic inhibitor of MMP-2/-9 Agouron 
COL-3 phase I + II synthetic inhibitor of MMPs Collagenex
Neovastat phase I + II endogenous inhibitor of MMPs Aeterna 
BMS-275291 phase I synthetic inhibitor of MMPs Bristol-Myers Squibb
CGS-27023A phase I + II synthetic inhibitor of MMPs Novartis 
Bay-12–9566 phase III synthetic inhibitor of MMP-2 /-9 Bayer 
TNP-470 phase I + II Fumagillin-analogue TAP pharmaceuticals 
Thalidomide phase I + II + III inhibits EC proliferation;
inhibits EC activation via monocyte by TNFα blockade Celgene 
Squalamine phase I + II extract from shark liver;
inhibits sodium-hydrogen exchanger, NHE3 Magainin Pharmaceuticals
Combrestatin A-4 prodrug phase I + II apoptosis of endothelial cells Oxigene 
Endostatin phase I inhibits endothelial proliferation Entremed
Angiostatin phase I inhibits EC proliferation Entremed
SU5416 phase I + II + III blocks VEGF receptor signaling Sugen 
SU101 phase III blocks PDGF receptor signaling Sugen 
SU6668 phase I blocks VEGF, FGF, PDGF receptor signaling Sugen 
Interferon-a phase II + III inhibition of bFGF, VEGF, and MMP-9 production Multiple vendors
Interferon-ß phase II + III inhibition of endothelial cell migration and morphogenesis Multiple vendors
Anti-VEGF Ab phase I + II humanized monoclonal antibody to VEGF Genentech 
EMD121974 phase I blocks αvβ3 integrins on EC Merck KcgaA Darmstadt
CAI phase I + II + III inhibits Ca++ influx National Cancer Institute, USA.
Interleukin-12 phase I + II upregulation of interferon-γ and IL-10 Genetics Institute
IM-862 phase I + II + III upregulates IL-12;
inhibits VEGF and bFGF production Cytran 
IMC-C225 phase I + II + III humanized monoclonal antibody to the EGF receptor ImClone 
IMC-1C11 phase I humanized monoclonal antibody to the VEGF receptor KDR ImClone 
Vitaxin phase I humanized monoclonal antibody to the αvβ3 integrin MedImmune / Ixsys
Anti-VEGF Ab phase II + III humanized monoclonal antibody to VEGF Genentech 
Suramin phase II prevents PDGF binding Multiple vendors
Troponin-I, BLS 0597 phase I inhibits EC proliferation, binds ATP synthase Boston Life Sciences
(fragment of troponin I)
Angiozyme phase I ribozyme degrades VEGF mRNA Ribozyme 
PTK787 / ZK-222584 phase I specific inhibitor of FLK-1 and KDR receptor for VEGF Novartis, Schering
Pentosan polysulfate phase I downregulates bFGF production Georgetown University, Washington
ZD-0101 phase I + II endotoxin binds to EC and induces antiinflammatory AstraZeneca / CarboMed 
CM-101 response
VEGF and VEGF-R2 downregulation
cific surface receptors with tyrosine kinase activity. The physi-
ologic function of Tie receptors and their ligands, called an-
giopoietins (ANG), in angiogenesis has only recently been
elucidated. ANG-1, the major physiologic activator of Tie-2,
promotes blood vessel maturation and stability. ANG-2 coun-
teracts this effect by competitively inhibiting the binding of
ANG-1 to Tie-2. Knock-out mice lacking the Tie receptors did
not survive beyond embryonic stages [23]. While Tie-1–/– mice
failed to establish the structural integrity of vascular endothe-
lial cells leading to localized hemorrhage, Tie-2–/– mice dis-
played significant abnormalities in growth and organization of
the vasculature [23]. Upregulation of ANG-2 by hypoxia oc-
curs in endothelial cells in vitro and in vivo [24]. Counteract-
ing VEGF-induced permeability, ANG-1 functions as an anti-
permeability factor when administered chronically during ves-
sel formation [25, 26].
Expression of ANG-1 or ANG-2 has not been detected in
normal brains. However, upregulation of Tie-2-receptor
mRNA and ANG-2 mRNA was demonstrated in endothelial
cells of glioma vasculature, while ANG-1 was found to be up-
regulated in glioma cells suggesting a role for angiopoietins in
glioma angiogenesis [27–29]. Application of the soluble extra-
cellular domain of Tie-2-inhibited angiogenesis in the rat
cornea, as well as tumor growth in a skin window chamber
[30]. Adenoviral delivery of a recombinant, soluble Tie-2 re-
ceptor suppressed murine mammary carcinoma or melanoma
growth and development of metastasis in mice [31].
Integrins and Matrix Metalloproteinases
Invasion and migration requires a complex interaction be-
tween tumor cells and extracellular matrix (ECM) compo-
nents. Tumor cell invasion involves cell-matrix adhesion,
chemotaxis, cell migration and proteolysis. Endothelial cells
interact with ECM proteins such as fibronectin via specific re-
ceptors expressed on their cell surface. They eventually invade
and dissolve the basement membrane and the surrounding
matrix by secretion of enzymes. This proteolytic degradation
of the ECM plays a central role in cancer invasion as well as in
non-neoplastic remodeling processes. The integrin family of
heterodimeric glycopeptides, particularly αvβ3 and αvβ5 inte-
grins, serve as major receptors for ECM-mediated cell adhe-
sion and migration. αvβ3 and αvβ5 integrins have been demon-
strated to be upregulated during repair, retinal neovasculari-
sation, and tumor neo-angiogenesis [32, 33]. αvβ3 integrins are
expressed in small blood vessels of glioblastoma [34]. Anti-
bodies to a variety of integrins have been shown to inhibit ma-
trigel invasion of glioma cell lines and primary cultures [35]. 
Among the key enzymes which participate in ECM degrada-
tion are the metalloproteases (MMP), zinc-binding endopepti-
dases such as MMP-2 and MMP-9, and serine proteases such
as tissue plasminogen activator (tPA) and urokinase plasmino-
gen activator (uPA). MMPs are secreted as inactive proen-
zymes and become activated at the site of action, e.g. the
tumor cell. An imbalance between MMPs and their naturally
occurring inhibitors, so-called tissue inhibitors of metallopro-
teinases (TIMP) has been observed in a variety of tumors, in-
cluding brain tumors [36–39]. The serine proteases, tPA and
uPA, activate the proenzyme plasminogen to plasmin, which
in turn is responsible for fibrinolytic activity. Consistent with
their role in cancer spread, elevated levels of both enzymes
have been associated with poor prognosis in a variety of tu-
mors. 
Matrix metalloproteinase-2 and integrin αvβ3 are functionally
associated on the surface of angiogenic blood vessels. MMP-2
(also called collagenase IV or gelatinase A) has been shown to
cleave type IV collagen, the major structural component of
basement membranes, with high specificity. Moreover, the
metastatic potential of tumor cells has been correlated with
the activity of this enzyme [40]. Short peptides which target
MMP-2 and MMP-9 inhibited the migration of human en-
dothelial and tumor cells and improved survival of mice bear-
ing human tumors [41]. Synthetic MMP inhibitors such as
Marimastat, Batimastat, AG3340, Bay 12–9556, and others are
already subject of clinical trials. 
Endogenous Inhibitors
Only recently we have witnessed the discovery of a number of
naturally occuring endogenous inhibitors of angiogenesis. Be-
sides primarily anti-angiogenic molecules such as platelet-de-
rived factor 4, or thrombospondin-1, a growing number of
anti-angiogenic factors such as angiostatin and endostatin rep-
resent proteolytic fragments of proteins with various functions
that may be unrelated to angiogenesis (table 3). 
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Interferons, esp. interferon-α and -ß 
PF4 (platelet-derived factor 4)
Thrombospondin-1
Metallospondin
TIMPs (tissue inhibitors of metalloproteinases)
Plasminogen activator/inhibitor
ANG-2 (angiopoietin-2) in absence of VEGF
SPARC (secreted protein, acidic and rich in
cysteine)
Angiostatin (cleaved from plasminogen)
Endostatin (cleaved from collagen XVIII)
PEX (cleaved from MMP-2)
N-terminal fragment of anti-thrombin III
16-kDa fragment of prolactin
Tn-1 (cleaved from Troponin-1)
Vasostatin (cleaved from calreticulin)
AaAT111 (cleaved from ATIII)
Arresten (cleaved from collagen type IV)
Canstatin (cleaved from collagen type IV)
Restin (cleaved from collagen type XV)
N-terminal fragment of platelet factor 4
Proliferin-related protein 
(cleaved from proliferin)
Table 3. Endoge-
nous inhibitors of 
angiogenesis
Thrombospondin
Activated platelets, endothelial cells, and fibroblasts release
several thrombospondin isoforms (TSP 1–4), a 450-kD ho-
motrimeric glycoprotein with a broad tissue distribution. TSP-
1 and TSP-2 were shown to inhibit endothelial cell prolifera-
tion, angiogenesis, and tumor growth [42, 43]. The p53 gene, a
major cell cycle regulator and tumor-suppressor gene, was
proposed to inhibit angiogenesis by regulation of TSP-1 syn-
thesis [44]. This finding is of special interest, as loss of p53 is a
common event in human cancer, especially in glioma. Upon
introduction of a wild-type chromosome 10 into 3 human
glioblastoma cell lines, their ability to form tumors in nude
mice was lost and an anti-angiogenic phenotype was acquired
[45]. Although chromosome 10 harbors a number of potential
tumor-suppressor genes, including the PTEN gene, the ob-
served change in angiogenesis was thought to be attributable
to the induction of thrombospondin-1 secretion, because a
neutralizing thrombospondin antibody completely relieved
the inhibition [45]. Similarly, thrombospondin-2 was shown to
be a potent inhibitor of angiogenesis and tumor growth in
mice after transfection into squamous cell carcinoma cells, al-
though its expression did not alter tumor cell proliferation or
apoptosis in vitro [43]. Moreover, the combined overexpres-
sion of TSP-1 and TSP-2 completely prevented tumor forma-
tion in this model [43]. Recently, short peptide fragments orig-
inating from the TSP protein have been shown to exhibit sim-
ilar anti-angiogenic properties and, thus, represent potential
candidates for the use in anti-angiogenetic therapy [46, 47]. 
Angiostatin
The discovery of the first highly specific anti-angiogenic mole-
cule, termed angiostatin, by O’Reilly et al. [48] has highlighted
the central role of angiogenesis in tumor development. This
initiated a search for new endogenous inhibitors of tumor-re-
lated angiogenesis. The search for an endogenous inhibitor of
tumor growth was based on the observation that metastases
began to grow after the removal of the original solid tumor.
When serum and concentrated urine from Lewis lung cell
(LLC) carcinoma bearing mice were given to mice that had
undergone removal of a solid LLC, a significant suppression
of metastases was observed suggesting the presence of a solu-
ble growth inhibitory mediator in these fluids. Interestingly,
serum and urine from LLC-bearing mice inhibited endothelial
cell proliferation, but had no effect on tumor cell proliferation
in vitro. The purified mediator, termed angiostatin, was identi-
fied as a 38-kDa amino-terminal fragment of plasminogen
spanning the first 4 kringle domains of plasminogen [48]. Fur-
ther investigations have shown that kringles 1–3 harbour the
endothelial cell inhibitory function, whereas kringle 4 had lit-
tle effect [49, 50]. However, a longer plasminogen fragment
encompassing kringles 1–5 is also an effective inhibitor of en-
dothelial cells and of tumor growth [51]. The observation of
angiostatin-induced apoptosis of endothelial but not of tumor
cells, indicates that endothelial cells and endothelial precur-
sor cells are exclusive cellular targets of angiostatin [48, 52]. In
addition, angiostatin has been shown to inhibit endothelial cell
migration and invasion, as well as tube formation in vitro [50,
53]. Angiostatin therapy keeps LLC lung metastases in a dor-
mant state which is characterized by insufficient vascularisa-
tion and high proliferation balanced by a high apoptotic rate
[4, 48, 54]. Subcutaneous and intracerebral gliomas of both rat
and human origin were successfully treated in a nude mouse
model by systemic administration of angiostatin [55, 56]. In
addition, retroviral or adenoviral transduction of the angio-
statin gene into established brain tumors in mice inhibited
tumor growth effectively [57, 58]. To date, many other extrac-
erebral tumor types have been demonstrated to respond with
growth inhibition to systemic application of angiostatin in vivo
[4, 48, 54]. Furthermore, the administration of angiostatin in
conjunction with ionizing radiation resulted in synergistic ef-
fects of the two modalities in 4 different cancer types in mice
including mouse LLC, human prostate and larynx squamous
cell carcinomas, as well as human D54 glioma [59, 60]. 
Endostatin
Using an experimental approach similar to that used for the
isolation of angiostatin, O’Reilly et al. [61] isolated endostatin,
a 22-kDa carboxy-terminal fragment of collagen XVIII α1,
from a murine hemangioendothelioma. Similarly to angio-
statin, it acts anti-angiogenic by induction of apoptosis and
specific inhibition of proliferation, migration, and tube forma-
tion of endothelial cells [61–63]. Endostatin has successfully
been used systemically or by gene transfer to treat a variety of
cancers including fibrosarcoma, melanoma, hemangiothe-
lioma, prostate, renal, mammary, lung, and colon carcinoma
[61]. Treatment of mice carrying fibrosarcoma, melanoma or
LLC with exogenously administered endostatin for several cy-
cles resulted in a permanent size reduction of tumors into
small, dormant nodules [64]. The combined application of an-
giostatin and endostatin has shown synergistic effects on
tumor suppression indicating that the molecular targets differ
between the two inhibitory molecules [65]. Recombinant en-
dostatin is currently subject of clinical trials for a variety of
cancers (table 2).
Synthetic Anti-Angiogenic Factors
Suramin
Suramin was initially introduced 80 years ago as a potent anti-
trypanozomal agent. Only recently, it was shown to inhibit
binding of platelet derived growth factor (PDGF) to its recep-
tor by binding to PDGF directly [66]. Thus, suramin acts anti-
angiogenic by disrupting the PDGF feedback loop operating
in many tumors, including brain tumors [67]. Suramin was also
shown to inhibit VEGF-induced tyrosine phosphorylation of
KDR in intact cells and to suppress bFGF-induced angiogene-
sis, tube formation, and matrigel invasion [68]. Its growth sup-
Onkologie 2001;24:423–430Therapeutic Anti-Angiogenesis for Malignant
Brain Tumors
427
pressive properties have been demonstrated for a number of
tumors including glioma and meningioma [69–72]. Suramin is
under clinical investigation (table 2).
Fumagillin and TNP 470
Fumagillin is a secreted antibiotic of the fungus Aspergillus
fumigatus. Its inhibitory property on endothelial cell prolifera-
tion was first noted in contaminated endothelial cell culture
dishes. Fumagillin was also shown to inhibit tumor-induced
angiogenesis in vivo [73]. More potent synthetic derivatives of
fumagillin are TNP-470 or AMG-1470 [74]. TNP-470 has been
demonstrated to reduce endothelial cell proliferation by inhi-
bition of urokinase-type plasminogen activator [75]. In addi-
tion, it acts growth suppressive on hematopoietic progenitor
cells [76]. While there are controversial reports on the effects
of TNP-470 on growth suppression of tumor cells in vitro, sev-
eral in vivo experiments have clearly demonstrated its growth-
suppressive effect on primary and metastatic tumor growth,
including pituitary adenoma, meningioma, medulloblastoma,
and glioma [77–82]. TNP-470 has entered clinical trials for a
variety of solid tumors including AIDS-associated Kaposi’s
sarcoma, prostate, cervical and pancreatic cancers, as well as
malignant glioma. 
Thalidomide
Thalidomide was initially developed as a compound to treat
morning sickness and headaches of pregnant women, but has
become known for its devastating teratogenic effects. Because
of its anti-angiogenic properties it is assumed that inhibition of
vascular development during embryogenesis accounts for its
teratogenicity [83]. While thalidomide inhibits endothelial cell
and tumor cell proliferation in vitro, it has variable inhibitory
effects on tumor growth and on the migration of metastases
[84, 85]. Thalidomide or its metabolites have been demon-
strated to repress the transcriptional activity of genes encod-
ing growth factors and integrins by binding to regulatory pro-
moter sequences. In addition, it was shown to interact syner-
gistically with other chemotherapeutic drugs in vivo. A recent
phase II study on the effects of thalidomide in advanced
melanoma, renal cell, ovarian and breast cancer has revealed
only modest therapeutic effects in renal cell carcinoma with
the other tumor types remaining unaffected [86]. However,
thalidomide has shown considerable effects even as a single
agent in patients with multiple myeloma and hepatocellular
carcinoma [87, 88]. Clinical trials for AIDS-related Kaposi
sarkoma and other types of cancer are being conducted. The
findings of a recently conducted phase II trial on Thalidomide
in patients with high-grade gliomas demonstrated low toxicity
and only minor responses to treatment [89]. 
Conclusion
The promising experimental data on anti-angiogenic interven-
tion in the treatment of cancer, both in vitro and in vivo, for
the treatment of experimental primary brain tumors and for
metastases warrant clinical investigation of anti-angiogenic
substances in human cancer. Compared to conventional
chemotherapeutics, anti-angiogenic substances have less toxic
side effects and are less likely to develop drug resistance. Es-
pecially with regard to the highly vascularized glioblastoma
that still carries a dismal prognosis, anti-angiogenic strategies
may offer new hope. In a clinical setting therapeutic anti-
angiogenesis could be applied pre-surgically for devascular-
ization, post-surgically to prevent recurrence of microscopic
residual tumor with or without the combination of established
cytotoxic drugs or radiation therapy. 
428 Onkologie 2001;24:423–430 Kirsch/Santarius/Black/Schackert
References
1 Brem S, Cotran R, Folkman J: Tumor angiogenesis:
A quantitative method for histologic grading. J
Natl Cancer Inst 1972;48:347–356.
2 Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick
M, Barnes P, Scott RM, Black PM, Sallan SE, Folk-
man J: Microvessel count and cerebrospinal fluid
basic fibroblast growth factor in children with brain
tumours. Lancet 1994;344:82–86.
3 Leon SP, Folkerth RD, Black PM: Microvessel den-
sity is a prognostic indicator for patients with as-
troglial brain tumors. Cancer 1996;77:362–372.
4 Holmgren L, O’Reilly MS, Folkman J: Dormancy
of micrometastases: Balanced proliferation and
apoptosis in the presence of angiogenesis suppres-
sion. Nat Med 1995;1:149–153.
5 Damert A, Machein M, Breier G, Fujita MQ,
Hanahan D, Risau W, Plate KH: Up-regulation of
vascular endothelial growth factor expression in a
rat glioma is conferred by two distinct hypoxia-dri-
ven mechanisms. Cancer Res 1997;57:3860–3864.
6 Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D,
Shih CC, Arap W, Huang CM, Cavenee WK: Sup-
pression of glioblastoma angiogenicity and tumori-
genicity by inhibition of endogenous expression of
vascular endothelial growth factor. Proc Natl Acad
Sci USA 1996;93:8502–8507.
7 Plate KH, Breier G, Weich HA, Risau W: Vascular
endothelial growth factor is a potential tumour an-
giogenesis factor in human gliomas in vivo. Nature
1992;359:845–848.
8 Brown LF, Berse B, Jackman RW, Tognazzi K,
Guidi AJ, Dvorak HF, Senger DR, Connolly JL,
Schnitt SJ: Expression of vascular permeability fac-
tor (vascular endothelial growth factor) and its re-
ceptors in breast cancer. Hum Pathol 1995;26:
86–91.
9 Detmar M, Velasco P, Richard L, Claffey KP, Streit
M, Riccardi L, Skobe M, Brown LF: Expression of
vascular endothelial growth factor induces an inva-
sive phenotype in human squamous cell carcino-
mas. Am J Pathol 2000;156:159–167.
10 Samoto K, Ikezaki K, Ono M, Shono T, Kohno K,
Kuwano M, Fukui M: Expression of vascular en-
dothelial growth factor and its possible relation
with neovascularization in human brain tumors.
Cancer Res 1995;55:1189–1193.
11 Plate KH, Breier G, Millauer B, Ullrich A, Risau
W: Up-regulation of vascular endothelial growth
factor and its cognate receptors in a rat glioma
model of tumor angiogenesis. Cancer Res 1993;53:
5822–5827.
12 Kalkanis SN, Carroll RS, Zhang J, Zamani AA,
Black PM: Correlation of vascular endothelial
growth factor messenger RNA expression with per-
itumoral vasogenic cerebral edema in menin-
giomas. J Neurosurg 1996;85:1095–101.
13 Provias J, Claffey K, delAguila L, Lau N, Feldkamp
M, Guha A: Meningiomas: Role of vascular en-
dothelial growth factor/vascular permeability factor
in angiogenesis and peritumoral edema. Neuro-
surgery 1997;40:1016–1026.
14 Strugar J, Rothbart D, Harrington W, Criscuolo
GR: Vascular permeability factor in brain metas-
tases: Correlation with vasogenic brain edema and
tumor angiogenesis. J Neurosurg 1994;81:560–566.
15 Strugar JG, Criscuolo GR, Rothbart D, Harrington
WN: Vascular endothelial growth/permeability fac-
tor expression in human glioma specimens: Corre-
lation with vasogenic brain edema and tumor-asso-
ciated cysts. J Neurosurgery 1995;83:682–689.
16 Oehring RD, Miletic M, Valter MM, Pietsch T,
Neumann J, Fimmers R, Schlegel U: Vascular en-
dothelial growth factor (VEGF) in astrocytic
gliomas – a prognostic factor? J Neurooncol 1999;
45:117–125.
17 Abdulrauf SI, Edvardsen K, Ho KL, Yang XY,
Rock JP, Rosenblum ML: Vascular endothelial
growth factor expression and vascular density as
prognostic markers of survival in patients with low-
grade astrocytoma. J Neurosurg 1998;88:513–520.
18 Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N:
Complete inhibition of angiogenesis and growth of
microtumors by anti-vascular endothelial growth
factor neutralizing antibody: Novel concepts of an-
giostatic therapy from intravital videomicroscopy.
Cancer Res 1996;56:4032–4039.
19 Zhu Z, Witte L: Inhibition of tumor growth and
metastasis by targeting tumor-associated angiogen-
esis with antagonists to the receptors of vascular
endothelial growth factor. Invest New Drugs 1999;
17:195–212.
20 Olson TA, Mohanraj D, Roy S, Ramakrishnan S:
Targeting the tumor vasculature: Inhibition of
tumor growth by a vascular endothelial growth fac-
tor-toxin conjugate. Int J Cancer 1997;73:865–870.
21 Sasaki M, Wizigmann-Voos S, Risau W, Plate KH:
Retrovirus producer cells encoding antisense
VEGF prolong survival of rats with intracranial
GS9L gliomas. Int J Dev Neurosci 1999;17:579–591.
22 D’Angelo G, Struman I, Martial J, Weiner RI: Acti-
vation of mitogen-activated protein kinases by vas-
cular endothelial growth factor and basic fibroblast
growth factor in capillary endothelial cells is inhib-
ited by the antiangiogenic factor 16-kDa N-termi-
nal fragment of prolactin. Proc Natl Acad Sci USA
1995;92:6374–6378.
23 Dumont DJ, Gradwohl G, Fong GH, Puri MC,
Gertsenstein M, Auerbach A, Breitman ML: Dom-
inant-negative and targeted null mutations in the
endothelial receptor tyrosine kinase, tek, reveal a
critical role in vasculogenesis of the embryo. Genes
Dev 1994;8:1897–1909.
24 Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pit-
tet B, Pepper MS: Hypoxia-inducible angiopoietin-
2 expression is mimicked by iodonium compounds
and occurs in the rat brain and skin in response to
systemic hypoxia and tissue ischemia. Am J Pathol
2000;156:2077–2089.
25 Thurston G, Suri C, Smith K, McClain J, Sato TN,
Yancopoulos GD, McDonald DM: Leakage-resis-
tant blood vessels in mice transgenically overex-
pressing angiopoietin-1. Science 1999;286:2511–
2514.
26 Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L,
Croll SD, Glazer N, Holash J, McDonald DM, Yan-
copoulos GD: Angiopoietin-1 protects the adult
vasculature against plasma leakage. Nat Med 2000;
6:460–463.
27 Stratmann A, Risau W, Plate KH: Cell type-specific
expression of angiopoietin-1 and angiopoietin-2
suggests a role in glioblastoma angiogenesis [see
comments]. Am J Pathol 1998;153:1459–1466.
28 Zagzag D, Amirnovin R, Greco MA, Yee H, Ho-
lash J, Wiegand SJ, Zabski S, Yancopoulos GD,
Grumet M: Vascular apoptosis and involution in
gliomas precede neovascularization: A novel con-
cept for glioma growth and angiogenesis. Lab In-
vest 2000;80:837–849.
29 Zagzag D, Hooper A, Friedlander DR, Chan W,
Holash J, Wiegand SJ, Yancopoulos GD, Grumet
M: In situ expression of angiopoietins in astrocy-
tomas identifies angiopoietin-2 as an early marker
of tumor angiogenesis. Exp Neurol 1999;159:391–
400.
30 Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Pe-
ters K: Inhibition of tumor angiogenesis using a sol-
uble receptor establishes a role for Tie2 in patho-
logic vascular growth. J Clin Invest 1997;100:2072–
2078.
31 Lin P, Buxton JA, Acheson A, Radziejewski C,
Maisonpierre PC, Yancopoulos GD, Channon KM,
Hale LP, Dewhirst MW, George SE, Peters KG:
Antiangiogenic gene therapy targeting the en-
dothelium-specific receptor tyrosine kinase Tie2.
Proc Natl Acad Sci USA 1998;95:8829–8834.
32 Brooks PC, Clark RA, Cheresh DA: Requirement
of vascular integrin alpha v beta 3 for angiogenesis.
Science 1994;264:569–571.
33 Brooks PC, Montgomery AM, Rosenfeld M, Reis-
feld RA, Hu T, Klier G, Cheresh DA: Integrin
alpha v beta 3 antagonists promote tumor regres-
sion by inducing apoptosis of angiogenic blood ves-
sels. Cell 1994;79:1157–1164.
34 Gladson CL: Expression of integrin alpha v beta 3
in small blood vessels of glioblastoma tumors. J
Neuropathol Exp Neurol 1996;55:1143–1149.
35 Paulus W, Tonn JC: Basement membrane invasion
of glioma cells mediated by integrin receptors. J
Neurosurg 1994;80:515–519.
36 Nakagawa T, Kubota T, Kabuto M, Fujimoto N,
Okada Y: Secretion of matrix metalloproteinase-2
(72 kD gelatinase/type IV collagenase = gelatinase
A) by malignant human glioma cell lines: Implica-
tions for the growth and cellular invasion of the ex-
tracellular matrix. J Neurooncol 1996;28:13–24.
37 Tupchong L, Levison DA, Jones AE: Concomitant
conjugal gliomas with similar histologic features.
Cancer 1985;55:864–869.
38 Deryugina EI, Bourdon MA, Luo GX, Reisfeld
RA, Strongin A: Matrix metalloproteinase-2 acti-
vation modulates glioma cell migration. J Cell Sci
1997;110:2473–2482.
39 Vince GH, Wagner S, Pietsch T, Klein R, Gold-
brunner RH, Roosen K, Tonn JC: Heterogeneous
regional expression patterns of matrix metallopro-
teinases in human malignant gliomas. Int J Dev
Neurosci 1999;17:437–445.
40 Kleiner DE, Stetler-Stevenson WG: Matrix metal-
loproteinases and metastasis. Cancer Chemother
Pharmacol 1999;43(suppl):S42–51:S42–S51.
41 Koivunen E, Arap W, Valtanen H, Rainisalo A,
Medina OP, Heikkila P, Kantor C, Gahmberg CG,
Salo T, Konttinen YT, Sorsa T, Ruoslahti E,
Pasqualini R: Tumor targeting with a selective
gelatinase inhibitor. Nat Biotechnol 1999;17:768–
774.
42 Streit M, Velasco P, Brown LF, Skobe M, Richard
L, Riccardi L, Lawler J, Detmar M: Overexpression
of thrombospondin-1 decreases angiogenesis and
inhibits the growth of human cutaneous squamous
cell carcinomas. Am J Pathol 1999;155:441–452.
43 Streit M, Riccardi L, Velasco P, Brown LF, Haw-
ighorst T, Bornstein P, Detmar M: Throm-
bospondin-2: A potent endogenous inhibitor of
tumor growth and angiogenesis. Proc Natl Acad Sci
USA 1999;96:14888–14893.
44 Dameron KM, Volpert OV, Tainsky MA, Bouck N:
Control of angiogenesis in fibroblasts by p53 regu-
lation of thrombospondin-1. Science 1994;265:
1582–1584.
45 Hsu SC, Volpert OV, Steck PA, Mikkelsen T,
Polverini PJ, Rao S, Chou P, Bouck NP: Inhibition
of angiogenesis in human glioblastomas by chromo-
some 10 induction of thrombospondin-1. Cancer
Res 1996;56:5684–5691.
46 Dawson DW, Volpert OV, Pearce SF, Schneider AJ,
Silverstein RL, Henkin J, Bouck NP: Three distinct
D-amino acid substitutions confer potent antian-
giogenic activity on an inactive peptide derived
from a thrombospondin-1 type 1 repeat. Mol Phar-
macol 1999;55:332–338.
47 Tolsma SS, Volpert OV, Good DJ, Frazier WA,
Polverini PJ, Bouck N: Peptides derived from two
separate domains of the matrix protein throm-
bospondin-1 have anti-angiogenic activity. J Cell
Biol 1993;122:497–511.
48 O’Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Moses M, Lane WS, Cao Y, Sage
EH, Folkman J: Angiostatin: A novel angiogenesis
inhibitor that mediates the suppression of metas-
tases by a Lewis lung carcinoma. Cell 1994;79:315–
328.
49 MacDonald NJ, Murad AC, Fogler WE, Lu Y, Sim
BK: The tumor-suppressing activity of angiostatin
protein resides within kringles 1 to 3. Biochem Bio-
phys Res Commun 1999;264:469–477.
50 Cao Y, Ji RW, Davidson D, Schaller J, Marti D,
Sohndel S, McCance SG, O’Reilly MS, Llinas M,
Folkman J: Kringle domains of human angiostatin.
Characterization of the anti-proliferative activity
on endothelial cells. J Biol Chem 1996;271:29461–
29467.
51 Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J,
Shi GY, Cao Y: Suppression of angiogenesis and
tumor growth by the inhibitor K1–5 generated by
plasmin-mediated proteolysis. Proc Natl Acad Sci
USA 1999;96:5728–5733.
52 Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ,
Quyyumi AA, Finkel T: Endothelial progenitor
cells as putative targets for angiostatin. Cancer Res
1999;59:5875–5877.
53 Claesson-Welsh L, Welsh M, Ito N, Ito N, Anand-
Apte B, Soker S, Zetter B, O’Reilly M, Folkman J:
Angiostatin induces endothelial cell apoptosis and
activation of focal adhesion kinase independently
of the integrin-binding motif RGD. Proc Natl Acad
Sci USA 1998;95:5579–5583.
54 O’Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Cao Y, Moses M, Lane WS, Sage
EH, Folkman J: Angiostatin: A circulating en-
dothelial cell inhibitor that suppresses angiogene-
sis and tumor growth. Cold Spring Harb Symp
Quant Biol 1994;59:471–482.
55 Kirsch M, Strasser J, Allende R, Bello L, Zhang J,
Black PM: Angiostatin suppresses malignant
glioma growth in vivo. Cancer Res 1998;58:4654–
4659.
56 Griscelli F, Li H, Bennaceur-Griscelli A, Soria J,
Opolon P, Soria C, Perricaudet M, Yeh P, Lu H:
Angiostatin gene transfer: Inhibition of tumor
growth in vivo by blockage of endothelial cell pro-
liferation associated with a mitosis arrest. Proc Natl
Acad Sci USA 1998;95:6367–6372.
Onkologie 2001;24:423–430Therapeutic Anti-Angiogenesis for Malignant
Brain Tumors
429
57 Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-
targeted antiangiogenic gene therapy utilizing an
angiostatin complementary DNA. Cancer Res
1998;58:3362–3369.
58 Fishel R, Lescoe MK, Rao M, Copeland NG, Jenk-
ins NA, Garber J, Kane M, Kolodner R: The
human mutator gene homolog msh2 and its associ-
ation with hereditary nonpolyposis colon cancer.
Cell 1993;75:1027–1038.
59 Mauceri HJ, Hanna NN, Beckett MA, Gorski DH,
Staba MJ, Stellato KA, Bigelow K, Heimann R,
Gately S, Dhanabal M, Soff GA, Sukhatme VP,
Kufe DW, Weichselbaum RR: Combined effects of
angiostatin and ionizing radiation in antitumour
therapy. Nature 1998;394:287–291.
60 Gorski DH, Mauceri HJ, Salloum RM, Gately S,
Hellman S, Beckett MA, Sukhatme VP, Soff GA,
Kufe DW, Weichselbaum RR: Potentiation of the
antitumor effect of ionizing radiation by brief con-
comitant exposures to angiostatin. Cancer Res
1998;58:5686–5689.
61 O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G,
Lane WS, Flynn E, Birkhead JR, Olsen BR, Folk-
man J: Endostatin: An endogenous inhibitor of an-
giogenesis and tumor growth. Cell 1997;88:277–285.
62 Dhanabal M, Ramchandran R, Waterman MJ, Lu
H, Knebelmann B, Segal M, Sukhatme VP: Endo-
statin induces endothelial cell apoptosis. J Biol
Chem 1999;274:11721–11726.
63 Yamaguchi N, Anand-Apte B, Lee M, Sasaki T,
Fukai N, Shapiro R, Que I, Lowik C, Timpl R,
Olsen BR: Endostatin inhibits VEGF-induced en-
dothelial cell migration and tumor growth indepen-
dently of zinc binding. EMBO J 1999;18:4414–4423.
64 Boehm T, Folkman J, Browder T, O’Reilly MS: An-
tiangiogenic therapy of experimental cancer does
not induce acquired drug resistance. Nature 1997;
390:404–407.
65 Yokoyama Y, Dhanabal M, Griffioen AW,
Sukhatme VP, Ramakrishnan S: Synergy between
angiostatin and endostatin: Inhibition of ovarian
cancer growth. Cancer Res 2000;60:2190–2196.
66 Hosang M: Suramin binds to platelet-derived
growth factor and inhibits its biological activity. J
Cell Biochem 1985;29:265–273.
67 Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo
A, Fogli S, Del Tacca M: Inhibitory effect of
suramin in rat models of angiogenesis in vitro and
in vivo. Cancer Chemother Pharmacol 1999;43:205–
212.
68 Gagliardi AR, Kassack M, Kreimeyer A, Muller G,
Nickel P, Collins DC: Antiangiogenic and antipro-
liferative activity of suramin analogues. Cancer
Chemother Pharmacol 1998;41:117–124.
69 Bernsen HJ, Rijken PF, Peters JP, Bakker JH,
Boerman RH, Wesseling P, van der Kogel AJ:
Suramin treatment of human glioma xenografts; ef-
fects on tumor vasculature and oxygenation status.
J Neurooncol 1999;44:129–136.
70 Coomber BL: Suramin inhibits C6 glioma-induced
angiogenesis in vitro. J Cell Biochem 1995;58:199–
207.
71 Firsching A, Nickel P, Mora P, Allolio B: Antipro-
liferative and angiostatic activity of suramin ana-
logues. Cancer Res 1995;55:4957–4961.
72 Schrell UM, Gauer S, Kiesewetter F, Bickel A,
Hren J, Adams EF, Fahlbusch R: Inhibition of pro-
liferation of human cerebral meningioma cells by
suramin: Effects on cell growth, cell cycle phases,
extracellular growth factors, and PDGF-BB au-
tocrine growth loop. J Neurosurg 1995;82:600–607.
73 Ingber D, Fujita T, Kishimoto S, Sudo K, Kana-
maru T, Brem H, Folkman J: Synthetic analogues
of fumagillin that inhibit angiogenesis and suppress
tumour growth. Nature 1990;348:555–557.
74 Castronovo V, Belotti D: TNP-470 (AGM-1470):
Mechanisms of action and early clinical develop-
ment. Eur J Cancer 1996;32A:2520–2527.
75 Maier JA, Delia D, Thorpe PE, Gasparini G: In
vitro inhibition of endothelial cell growth by the
antiangiogenic drug AGM-1470 (TNP-470) and the
anti-endoglin antibody TEC-11. Anticancer Drugs
1997;8:238–244.
76 Hasuike T, Hino M, Yamane T, Nishizawa Y, Morii
H, Tatsumi N: Effects of TNP-470, a potent angio-
genesis inhibitor, on growth of hematopoietic prog-
enitors [letter]. Eur J Haematol 1997;58:293–294.
77 Isobe N, Uozumi T, Kurisu K, Kawamoto K: Anti-
tumor effect of TNP-470 on glial tumors transplant-
ed in rats. Anticancer Res 1996;16:71–76.
78 Isobe N, Uozumi T, Kurisu K, Kawamoto K: Ex-
perimental studies of the antitumor effect of TNP-
470 on malignant brain tumors. Antitumor effect of
TNP-470 on a human medulloblastoma xenograft
line. Neuropediatrics 1996;27:136–142.
79 Takechi A, Uozumi T, Kawamoto K, Ito A, Kurisu
K, Sudo K: Inhibitory effect of TNP-470, a new
anti-angiogenic agent, on the estrogen induced rat
pituitary tumors. Anticancer Res 1994;14:157–162.
80 Taki T, Ohnishi T, Arita N, Hiraga S, Saitoh Y, Izu-
moto S, Mori K, Hayakawa T: Anti-proliferative ef-
fects of TNP-470 on human malignant glioma in
vivo: Potent inhibition of tumor angiogenesis. J
Neurooncol 1994;19:251–258.
81 Wassberg E, Pahlman S, Westlin JE, Christofferson
R: The angiogenesis inhibitor TNP-470 reduces the
growth rate of human neuroblastoma in nude rats.
Pediatr Res 1997;41:327–333.
82 Yazaki T, Takamiya Y, Costello PC, Mineta T,
Menon AG, Rabkin SD, Martuza RL: Inhibition of
angiogenesis and growth of human non-malignant
and malignant meningiomas by TNP-470. J Neu-
rooncol 1995;23:23–29.
83 D’Amato RJ, Loughnan MS, Flynn E, Folkman J:
Thalidomide is an inhibitor of angiogenesis. Proc
Natl Acad Sci USA 1994;91:4082–4085.
84 Moreira AL, Friedlander DR, Shif B, Kaplan G,
Zagzag D: Thalidomide and a thalidomide ana-
logue inhibit endothelial cell proliferation in vitro. J
Neurooncol 1999;43:109–114.
85 Minchinton AI, Fryer KH, Wendt KR, Clow KA,
Hayes MM: The effect of thalidomide on experi-
mental tumors and metastases. Anticancer Drugs
1996;7:339–243.
86 Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan
MM, Pyle L, Johnston SR, Ahern R, Smith IE,
Gore ME: Continuous low dose Thalidomide: A
phase II study in advanced melanoma, renal cell,
ovarian and breast cancer. Br J Cancer 2000;82:
812–817.
87 Juliusson G, Celsing F, Turesson I, Lenhoff S, Adri-
ansson M, Malm C: Frequent good partial remis-
sions from thalidomide including best response
ever in patients with advanced refractory and re-
lapsed myeloma [In Process Citation]. Br J Haema-
tol 2000;109:89–96.
88 Zomas A, Anagnostopoulos N, Dimopoulos MA:
Successful treatment of multiple myeloma relaps-
ing after high-dose therapy and autologous trans-
plantation with thalidomide as a single agent. Bone
Marrow Transplant 2000;25:1319–1320.
89 Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis
AP, Loeffler JS, Levin VA, Black PM, Kaplan R,
Pluda JM, Yung WK: Phase II trial of the antian-
giogenic agent thalidomide in patients with recur-
rent high-grade gliomas. J Clin Oncol 2000;18:708.
430 Onkologie 2001;24:423–430 Kirsch/Santarius/Black/Schackert
